Abiopharma

🔍 Connaughton Bernadette (Executive)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Sold 100 shares of Common Stock at $71.71 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,852.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,977 shares of Common Stock at $73.618 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 47,875.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 923 shares of Common Stock at $74.111 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 46,952.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.
• F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.91 to $73.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.95 to $74.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.